{
    "clinical_study": {
        "@rank": "119533", 
        "arm_group": [
            {
                "arm_group_label": "High dose of C. difficile vaccine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Low dose of C. difficile vaccine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate a Clostridium difficile vaccine in healthy adults aged 65 to 85\n      years, who will each receive 3 doses of vaccine.  The study will assess the safety and\n      tolerability of the vaccine, and also look at the subjects' immune response to the vaccine."
        }, 
        "brief_title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Clostridium Difficile Associated Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy male and female subjects aged 65 to 85 years\n\n        Exclusion Criteria:\n\n        Proven or suspected prior episode of Clostridium difficile associated diarrhea.\n\n        Unstable chronic medical condition or disease requiring significant change in therapy or\n        hospitalization for worsening disease within 8 weeks before receipt of study vaccine.\n\n        Any contraindication to vaccination or vaccine components, including previous anaphylactic\n        reaction to any vaccine or vaccine-related components."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "707", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117570", 
            "org_study_id": "B5091003"
        }, 
        "intervention": [
            {
                "arm_group_label": "High dose of C. difficile vaccine", 
                "description": "0.5 mL intramuscular injection on day 1, day 8, and day 30.", 
                "intervention_name": "Clostridium difficile vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Low dose of C. difficile vaccine", 
                "description": "0.5 mL intramuscular injection on day 1, day 8, and day 30.", 
                "intervention_name": "Clostridium difficile vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Clostridium difficile", 
            "vaccine"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5091003&StudyName=A%20Study%20To%20Investigate%20A%20Clostridium%20Difficile%20Vaccine%20In%20Healthy%20Adults%20Aged%2065%20to%2085%20Years%2C%20Who%20Will%20Each%20Receive%203%20Doses%20Of%2"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-Dose Regimen In Healthy Adults Aged 65 To 85 Years", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects in each treatment group with neutralizing antibody levels greater than or equal to specified thresholds at Day 37.", 
                "safety_issue": "No", 
                "time_frame": "Day 37"
            }, 
            {
                "measure": "Number of subjects reporting local reactions (pain, erythema, and induration) and their severity, as self reported on eDiaries for 7 days following each vaccination.", 
                "safety_issue": "Yes", 
                "time_frame": "For 7 days after vaccination"
            }, 
            {
                "measure": "Number of subjects reporting systemic reactions (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and their severity, as self reported on eDiaries for 7 days following each vaccination.", 
                "safety_issue": "Yes", 
                "time_frame": "For 7 days after vaccination"
            }, 
            {
                "measure": "Number of subjects reporting adverse events (AEs) up to 28 days after the last vaccination (Month 2) and serious adverse events (SAEs) throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "2 months (AEs); 13 months (SAEs)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117570"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Neutralizing antibody levels at various time points after vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months after last vaccination"
            }, 
            {
                "measure": "Number of subjects in each treatment group with 4 and higher fold-rises in neutralizing antibody levels at various time points after vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months after last vaccination"
            }, 
            {
                "measure": "Number of subjects in each treatment group with neutralizing antibody levels greater than or equal to specified thresholds at various time points after vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months after last vaccination"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}